Testing CMTS0929 for inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new treatment called CMTS0929 for people with inflammatory bowel disease (IBD), a condition that causes inflammation in the digestive tract. It aims to see if the treatment works and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with inflammatory bowel disease (IBD).
- You are between 18 and 75 years old.
- You have not used antibiotics, probiotics, or prebiotics in the past month.
- You are willing to follow the study plan and sign a consent form.
- You are not pregnant or planning to become pregnant during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests a new investigational drug called PVT401 in healthy people. It is a first-in-human study to see how the drug is handled by the body and to check for any side effects.
This trial tests a new treatment called CMTS0929 for people with C. diff infection. It aims to see if the treatment can help clear the infection and improve symptoms.
This study tests whether taking probiotics can help prevent or treat inflammatory bowel disease (IBD) in people recently diagnosed. It aims to see if friendly bacteria can calm gut inflammation and improve symptoms.
This trial tests a new treatment made from gut bacteria for people with irritable bowel syndrome that causes diarrhea (IBS-D). The treatment may help restore healthy gut bacteria and reduce symptoms.
This study tests if a standardized fecal transplant is safe and helpful for adults with moderately to severely active Crohn's disease who are already on maintenance therapy. The goal is to see if this treatment can reduce inflammation in the digestive tract.
Hear when a new Inflammatory Bowel Disease (IBD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.